Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Surgical Approach to Primary Lung Cancer and Metastatic Solid Tumors...
share announcement

Surgical Approach to Primary Lung Cancer and Metastatic Solid Tumors Involving the Lung

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 September 2024) | Viewed by 3342

Special Issue Editors

Dr. Diego Luigi Cortinovis

E-Mail Website
Guest Editor
1. Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy
2. Medicine and Surgery Department, University of Milano Bicocca, 20126 Milano, Italy
Interests: cancer therapy; oncology; thoracic malignancies; lung cancer; mesothelioma; esophagus cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Francesco Petrella

E-Mail Website
Guest Editor
Division of Thoracic Surgery, Fondazione IRCCS San Gerardo dei Tintori Monza, 20900 Monza, Italy
Interests: thoracic surgical oncology; augmented, virtual and mixed reality in surgery; holograms in surgery; chest wall resection and reconstruction; regenerative medicine and stem cells technology applied to surgery; ECMO for pulmonary/mediastinal resections; forensic medicine in thoracic surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Francesca Colonese

E-Mail Website
Guest Editor
Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori Hospital in Monza, Via Giambattista Pergolesi 33, 20900 Monza, Italy
Interests: immunotherapy; NSCLC
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lung cancer is the second most frequent tumor and the leading cause of cancer death among both women and men, causing almost 25% of all cancer deaths. On the other side, the lung is the second most frequent target of metastases that form solid tumors, and pulmonary metastasectomy represents the most common surgical procedure in thoracic surgery.

Historically, early-stage lung cancers have been treated by surgical resection in healthy patients and by radiotherapy in unfit or fragile patients not amenable to surgical approaches. Locally advanced lung cancer is usually treated by multimodal approaches, integrating induction treatments, surgical resection and adjuvant therapies. On the other hand, lung metastasectomy is an effective therapeutic alternative in selected patients, depending on primary tumor’s biology, disease-free interval, number and site of the nodule to be excised, planned extension of lung resection as well as available alternative therapeutic options. Another surgical option widely debated involves the field of synchronous or metachronous lung cancers paving the way to a personalized therapeutic strategy in particular in the era of immune-therapy and precision medicine.

In this Special Issue, we would like to analyze the most significant advancements in the therapy of both primary and secondary lung tumors.

It is our pleasure to lead such a wide Special Issue and we look forward to receiving your valuable participations.

You may choose our Joint Special Issue in Current Oncology.

Dr. Diego Luigi Cortinovis
Dr. Francesco Petrella
Dr. Francesca Colonese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • metastasectomy
  • immune-therapy
  • precision medicine
  • surgical resection

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1237 KiB  
Article
Long-Term Follow-Up after Laser-Assisted Pulmonary Metastasectomy Shows Complete Lung Function Recovery
by Daniel Baum, Axel Rolle, Dirk Koschel, Lysann Rostock, Rahel Decker, Monika Sombati, Florian Öhme and Till Plönes
Cancers 2024, 16(9), 1762; https://doi.org/10.3390/cancers16091762 - 1 May 2024
Viewed by 1219
Abstract
Preserving maximum lung function is a fundamental goal of parenchymal-sparing pulmonary laser surgery. Long-term studies for follow-up of lung function after pulmonary laser metastasectomy are lacking. However, a sufficient postoperative lung function is essential for quality of life and reduces potential postoperative complications. [...] Read more.
Preserving maximum lung function is a fundamental goal of parenchymal-sparing pulmonary laser surgery. Long-term studies for follow-up of lung function after pulmonary laser metastasectomy are lacking. However, a sufficient postoperative lung function is essential for quality of life and reduces potential postoperative complications. In this study, we investigate the extent of loss in lung function following pulmonary laser resection after three, six, and twelve months. We conducted a retrospective analysis using a prospective database of 4595 patients, focusing on 126 patients who underwent unilateral pulmonary laser resection for lung metastases from 1996 to 2022 using a 1318 nm Nd:YAG laser or a high-power pure diode laser. Results show that from these patients, a median of three pulmonary nodules were removed, with 75% presenting central lung lesions and 25% peripheral lesions. The median preoperative FEV1 was 98% of the predicted value, decreasing to 71% postoperatively but improving to 90% after three months, 93% after six months, and 96% after twelve months. Statistical analysis using the Friedman test indicated no significant difference in FEV1 between preoperative levels and those at six and twelve months post-surgery. The findings confirm that pulmonary laser surgery effectively preserves lung function over time, with patients generally regaining their preoperative lung function within a year, regardless of the metastases’ location. Full article
(This article belongs to the Special Issue Surgical Approach to Primary Lung Cancer and Metastatic Solid Tumors Involving the Lung)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 761 KiB  
Review
Colorectal Cancer Pulmonary Metastasectomy: When, Why and How
by Francesco Petrella, Federica Danuzzo, Maria Chiara Sibilia, Sara Vaquer, Raffaella Longarini, Alessandro Guidi, Federico Raveglia, Lidia Libretti, Emanuele Pirondini, Andrea Cara, Enrico Mario Cassina, Antonio Tuoro and Diego Cortinovis
Cancers 2024, 16(7), 1408; https://doi.org/10.3390/cancers16071408 - 3 Apr 2024
Viewed by 1650
Abstract
Colorectal cancer is the third-most-diagnosed cancer in males and in females, representing 8% of estimated new cases, and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients [...] Read more.
Colorectal cancer is the third-most-diagnosed cancer in males and in females, representing 8% of estimated new cases, and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9–12% are eligible for local treatments with radical intent, including surgical resection, SBRT (stereotactic body radiation therapy) and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy. Full article
(This article belongs to the Special Issue Surgical Approach to Primary Lung Cancer and Metastatic Solid Tumors Involving the Lung)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop